Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”line” assets=”OCTP.L” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] Oxford Cannabinoid
This week, British pharmaceutical cannabis firm Oxford Cannabinoid Technologies (OCT) announced that the ‘final dose’ in its crucial Phase I
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] The London Stock
OXFORD Cannabinoid Technologies Holdings plc (LSE: OCTP, OTCQB: OCTHF), the pharmaceutical company developing prescription cannabinoid medicines targeting the US$ multi-billion
We won’t spam you
